Respiratory imaging technology innovator 4DMedical Limited announced today its collaboration with Vanderbilt University Medical Center (VUMC) as part of a research grant awarded by the US Department of Veterans Affairs (VA).
The grant, facilitated by the Military Exposures Research Program (MERP), aims to advance understanding of the health effects associated with military exposures, particularly related to burn pits, the ASX-listed company said in a media release.
The agreement marks an achievement for 4DMedical, as its XV LVAS technology will be deployed at the Vanderbilt University Institute for Imaging Sciences (VUISS) in Nashville, Tennessee.
This cutting-edge hub for Veterans’ health research will utilize 4DMedical’s respiratory imaging technology to enhance assessments of military exposure impacts and inform care and policy decisions.
This partnership follows 4DMedical’s previous successful collaboration with VUMC, where XV Technology demonstrated its efficacy in diagnosing respiratory diseases in Veterans exposed to airborne hazards.
The study, conducted in partnership with the Nashville Veterans Affairs Medical Center, showcased XV Technology as a safer and more cost-effective alternative to conventional diagnostic methods such as CT scans and pulmonary function testing.
Dr Bradley W. Richmond, assistant professor in the Department of Allergy, Pulmonary, and Critical Care at Vanderbilt University Medical Center, expressed enthusiasm for the collaboration, highlighting the unique capabilities of 4DMedical’s XV Technology in evaluating lung function in real-time.
“Vanderbilt University Medical Center was one of the earliest collaborative partners of 4DMedical and is utilising 4DMedical’s X-ray Velocimetry software (XV Technology) to develop radiographic biomarkers for diagnosis and prognostication in multiple diseases including deployment-related respiratory disease (DRRD), candidate selection for bronchoscopic lung volume reduction (BLVR) in COPD, and in early diagnosis of chronic lung allograft dysfunction after lung transplantation,” he explained.
4DMedical’s MD/CEO and Founder Andreas Fouras underscored the company’s commitment to supporting Veterans’ health through innovative technology.
He underscored the importance of XV Technology in sensitively and non-invasively detecting lung disease associated with toxic exposure, further solidifying 4DMedical’s role as a leading technology provider in this critical field.
“This project, combined with our recent news regarding the use of Imbio’s LTA to detect pulmonary fibrosis in Veterans, highlights the growing profile and momentum 4D has at the VA, and I look forward to sharing further updates in the coming months,” Fouras concluded.
